middle.news
Argenica Boosts War Chest with $3.97M R&D Rebate Ahead of Phase 2b Stroke Trial
8:32am on Tuesday 17th of March, 2026 AEDT
•
Healthcare
Read Story
Argenica Boosts War Chest with $3.97M R&D Rebate Ahead of Phase 2b Stroke Trial
8:32am on Tuesday 17th of March, 2026 AEDT
Key Points
Received $3.97 million R&D tax incentive cash rebate for FY25
Proforma cash balance of $9 million as of 31 December 2025
Rebate includes newly approved overseas R&D activities
Advancing preparations for Phase 2b acute ischemic stroke trial
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Argenica Therapeutics (ASX:AGN)
OPEN ARTICLE